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The current treatment paradigm for 
Major Depressive Disorder
ajor Depressive Disorder (MDD) is a signifi-
cant public health problem. The annual costs of depres-
sion are estimated at 83.1 billion US dollars.
1 Nearly two
thirds of this cost comes from impaired productivity and
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Current treatment of Major Depressive Disorder utilizes a trial-and-error sequential treatment strategy that results in
delays in achieving response and remission for a majority of patients. Protracted ineffective treatment prolongs patient
suffering and increases health care costs. In addition, long and unsuccessful antidepressant trials may diminish patient
expectations, reinforce negative cognitions, and condition patients not to respond during subsequent antidepressant tri-
als, thus contributing to further treatment resistance. For these reasons, it is critical to identify reliable predictors of anti-
depressant treatment response that can be used to shorten or eliminate lengthy and ineffective trials. Research on pos-
sible endophenotypic as well as genomic predictors has not yet yielded reliable predictors. The most reliable predictors
identified thus far are symptomatic and physiologic characteristics of patients that emerge early in the course of treat-
ment. We propose here the term “response endophenotypes” (REs) to describe this class of predictors, defined as latent
measurable symptomatic or neurobiologic responses of individual patients that emerge early in the course of treatment,
and which carry strong predictive power for individual patient outcomes. Use of REs constitutes a new paradigm in which
medication treatment trials that are likely to be ineffective could be stopped within 1 to 2 weeks and other medication
more likely to be effective could be started. Data presented here suggest that early changes in symptoms, quantitative
electroencephalography, and gene expression could be used to construct effective REs. We posit that this new paradigm
could lead to earlier recovery from depressive illness and ultimately produce profound health and economic benefits.   
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DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 435absenteeism from work. Approximately 14.8 million
American adults
2 (6.7% of the population) suffer from
MDD, and cost employers more than $44 billion per
year in lost productive time and 387 million days per
year of disability.
1 While the economic costs are sub-
stantial, the personal costs of prolonged suffering are
incalculable. 
The costs of MDD are high, in part because it takes so
long for patients with MDD to recover from the illness.
Even after 1 year of treatment with enhanced resources
under a structured algorithm, only 11% of patients
achieved remission.
3This low recovery rate is not simply
a matter of needing more or better medications. There
are more than 20 treatments for MDD approved as
effective by the Food and Drug Administration (FDA).
The challenge is choosing the best treatment for each
patient. The current treatment guidelines for MDD of
the American Psychiatric Association
4 support a “watch-
ful waiting” approach to determine if a particular med-
ication will be useful for an individual patient. In order
to determine whether a medication will lead to response
(≥50% reduction in depressive symptoms) or remission
(nearly complete resolution of symptoms), it is recom-
mended that a physician wait to see if it will be effective.
4
On average, at least 4 weeks are needed to attain
response and 6 weeks to attain remission during treat-
ment with an initial selective serotonin reuptake
inhibitor (SSRI) antidepressant; in a number of cases,
however, remission can take 12 weeks or longer to
attain.
5 In practice, physicians commonly wait 6 to 8
weeks to determine if a patient will recover with
whichever medication is chosen.
6,7
It is not surprising that, under the current treatment par-
adigm, most patients face a long and frustrating course of
treatment. The Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) study, the largest study of
MDD conducted in the United States, showed that even
with enriched resources devoted to treatment, recovery
with the first selected SSRI occurred only about 30% of
the time.
8 More than 20% of those who failed to improve
with the first treatment simply stopped taking medication,
primarily within the first 2 weeks.
9Although medication
may take up to 12 weeks to be effective, 42% of patients
discontinue medication within the first 30 days.
10A high
proportion of the patients who prematurely stop treat-
ment are from ethnic minority groups,
10 and this may con-
tribute to the significantly poorer clinical outcomes
observed among ethnic minority patients.
11
Failure to respond to treatment at any one step is com-
monly followed by “sequential treatment” in which a
subsequent treatment is utilized either alone in combi-
nation,
12-14 followed by another period of watchful wait-
ing. In most studies, only about 15% of patients will ulti-
mately fail to benefit from sequential medication
treatment, but it may take 1 to 2 years to identify the
treatment that will get a patient well—and many dis-
continue treatment before they can recover.
15 For those
individuals who leave treatment prematurely, suffering,
disability, impaired productivity, and absenteeism from
work may continue indefinitely. For those who remain
in treatment, the delay in recovery from MDD increases
health care costs. While they are depressed, patients with
MDD have at least a 50% increase in total health care
costs for general medical conditions.
16
The current paradigm of watchful waiting is seriously
flawed. Lengthy medication trials determine with a high
degree of certainty whether a particular medication will
be effective. Because only a minority of patients will
recover with any one medication, however, this para-
digm prolongs the length of depressive episodes for most
patients, increases health care costs, and increases the
likelihood that many patients will drop out and never
receive adequate treatment. The approach of lengthy
medication trials essentially sacrifices the health of the
majority of patients for the certainty of knowing
whether a particular antidepressant will be effective. 
Limitations of the current 
treatment paradigm
In sequential treatment, subsequent antidepressant med-
ications commonly are selected based upon their puta-
tive mechanism of action (MOA), with medications that
have a different MOA usually given preference.
17 It has
never been shown, however, that MOA is related to
effectiveness in switching or combining medications.
18
The results from level II treatment in STAR*D sug-
gested that patients respond or remit to different anti-
depressants at similar rates, regardless of the MOA.
19,20
The sole reliable predictor of improvement in sequen-
tial treatment is that improvement at one step is asso-
ciated with further improvement at the next step,
whereas failure to improve indicates a poor prognosis
for improvement during future treatments.
19,21 The
STAR*D study demonstrated that each subsequent
medication trial was less and less likely to be effective
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level.
13,19,21-23
The development of increasing resistance over the
course of antidepressant treatment is well established
but not well understood. It largely has been interpreted
as representing the fact that those who fail to benefit
from adequate trials of earlier treatments are simply pre-
disposed not to respond to multiple treatments, some-
times because of comorbid conditions.
24 This hypothe-
sized process through which successive treatment
failures identify and isolate an increasingly treatment-
resistant population may account, at least in part, for the
escalation in failure rates with successive trials. This “dis-
tillation” hypothesis, however, is unlikely to account fully
for increasing treatment resistance with multiple anti-
depressant trials. Even within a trial of a single antide-
pressant medication, there is a great deal of hetero-
geneity in onset of improvement that is not easily
explained by commonly measured clinical features. Half
of patients require more than 6 weeks to enter remission
and a significant number of patients still enter remission
up to 12 weeks, yet these later remitters eventually may
attain a degree of improvement comparable to those
who enter remission rapidly.
5
A number of factors are likely to affect speed and com-
pleteness of medication responsiveness. Whereas some
of these factors may reflect heritable or constant bio-
logical factors, others may be more dynamic and repre-
sent the state of the individual at the specific time that
he or she enters treatment.
25-27 Many such intraindivid-
ual factors are psychological, including patient expec-
tations, cognitions, or conditioned responses. Data from
subjects enrolled in clinical trials has shown that
patients with high expectations of the effectiveness of
their treatment are more likely to benefit from their
treatment,
28,29 and to respond more rapidly.
29 Patients
who are uncertain about the benefit of their antide-
pressant treatment may even discontinue medication
before it has had time to work.
30These findings are con-
sistent with the fact that in the setting of a placebo con-
trolled trial, patients’ certainty that they will be receiv-
ing the active medication as compared with placebo is
directly related to their likelihood of response. Patients
who are informed that they have a 50% likelihood of
receiving active medication are significantly more likely
to respond than those who are informed that their prob-
ability of receiving medication is only 20%.
31 It is rea-
sonable to postulate that anything in the treatment set-
ting that alters patients’ expectations of improvement
is likely to alter their likelihood of benefiting from a
medication. Insofar as prolonged prior administration
of an ineffective antidepressant may diminish expecta-
tions of improvement, this practice may contribute to
the failure of subsequent trials. 
Cognitive theories of depression suggest that, in the con-
text of dysfunctional attitudes that subserve depression,
failed treatment attempts would perpetuate negative
thoughts and contribute to future failures. Beck’s cogni-
tive theory postulates that dysfunctional attitudes
develop in response to specific stressors in the midst of
an episode of depression.
32 The poorer treatment out-
comes of some depressive subtypes is partly explained
by the patients’ level of negative or dysfunctional cog-
nitions.
33 Depressed patients’ interpretation of negative
events also may increase the likelihood of maintaining
depression and of poor response to medication.
34,35 In the
midst of an episode of MDD, ineffective treatment trials
may constitute a specific stressor that, interpreted in a
negative context, could combine with dysfunctional atti-
tudes to result in increasingly resistant depression in
some patients. 
Classical conditioning also may play a role in antide-
pressant resistance during successive trials. Animal mod-
els have shown that pharmacologic responses to a num-
ber of different therapeutic agents can be classically
conditioned,
36,37 including responses to antidepressant
agents.
38 Similarly, pharmacologic nonresponse can also
be conditioned to a reuptake inhibitor drug.
39A related
concept in the classical conditioning paradigm is the
process of latent inhibition, in which frequent adminis-
tration of a cue (in this case, antidepressant pill-taking)
that is not associated with a significant outcome prevents
future conditioning to that cue.
40 There is evidence to
suggest that patients’ physiologic responses to antide-
pressant medications are in part conditioned responses.
A number of brain imaging studies have shown that
effective antidepressant treatment is associated with
decreases in metabolism or brain electrical activity in the
prefrontal cortex.
41,42 While these changes in function
appear to be associated with antidepressant treatment,
brain imaging during a placebo lead-in showed that the
changes thought to be associated with successful anti-
depressant treatment actually preceded administration
of the medication.
25 These findings suggest that a psy-
chological process such as conditioning plays a role in
eliciting brain functional changes. Whether nonresponse
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the clinical setting by prolonged nonresponse to antide-
pressants has not been established. 
It is difficult to demonstrate the role of expectations,
cognitions, or conditioned responses in the failure to
respond to successive antidepressant medication trials
in humans. It is known that administration of an antide-
pressant is less effective after the patient has received no
benefit from either a first antidepressant
21 or a placebo,
43
but multiple crossover trials would be necessary to
determine the mechanism for this loss of effectiveness.
There is clearer evidence from human pain studies, how-
ever, that ineffective medication trials directly contribute
to decreases in the effectiveness of subsequent analgesic
medications. The effectiveness of an analgesic medica-
tion is degraded when administered after an ineffective
dose of medication or placebo; furthermore, the more
doses of the ineffective compound that are given, the
less likely that the analgesic will have a therapeutic
effect.
44,45 Blinded administration of effective analgesics
also diminishes their effectiveness.
46 Expectations, con-
ditioning, and cognitive factors all have been shown to
be involved in mediating these effects.
46,47
In summary, unsuccessful antidepressant trials may
diminish patient expectations, reinforce negative cogni-
tions, and condition patients not to respond during sub-
sequent antidepressant trials. Regardless of the psycho-
logical mechanism, the above theories and data suggest
that ineffective medication trials may, in and of them-
selves, predispose patients to experience diminished
medication effectiveness in future trials. 
The state of endophenotypic 
and genomic predictors
There are several strategies that could be employed to
overcome the shortcomings of the current paradigm for
prescribing antidepressant medications. One of these
would be to identify, prior to treatment, the medication
that has the highest likelihood of benefitting the patient.
Research has sought to indentify “endophenotypes” that
could predict response or remission to specific antide-
pressants for individual patients. As defined by
Gottesman and Gould,
48 an endophenotype must meet
five criteria:
1. The endophenotype is associated with illness in the
population. 
2. The endophenotype is heritable. 
3. The endophenotype is primarily state-independent
(manifests in an individual whether or not illness
is active). 
4. Within families, endophenotype and illness coseg-
regate. 
5. The endophenotype found in affected family mem-
bers is found in nonaffected family members at a
higher rate than in the general population. 
Endophenotypes thus are measureable characteristics
or physiologic indices that fill “the gap between avail-
able descriptors and between the gene and the elusive
disease process.”
49 Exhaustive studies of clinical features,
family history, as well as sleep patterns and neuroen-
docrine correlates, have identified general prognostic
indicators for treatment outcome for depression.
50,51 In
some cases, the predictors may be useful for groups of
patients with certain subtypes of depression (ie, psy-
chotic depression).
52While some symptomatic and phys-
iologic features in MDD patients demonstrate promise
as putative endophenotypes, many do not fulfill the
actual criteria for an endophenotype or meet the goal of
providing greater prognostic specificity than the defini-
tion of the illness itself.
53 Some brain imaging findings
also have demonstrated prognostic significance
54-57 and
may fulfill the criteria for an endophenotype.
58 Part of
the challenge in identifying true endophenotypes in
MDD is that the physiologic and genetic underpinnings
of MDD are complex and poorly understood. As a
result, imaging findings may reflect confounds such as
interindividual heterogeneity in brain structure or func-
tion unrelated to illness, or the effects of previous or con-
comitant medication treatment.
58 No clinically meaning-
ful endophenotypes predictive of response to specific
medications in individual patients prior to the start of
treatment yet have been identified.
59,60
An alternative to the endophenotypic approach has
been to examine genetic polymorphisms as possible out-
come predictors. Recent studies have suggested that
common genetic variations may be associated with
response to specific antidepressant medications.
61-63 For
example, some common polymorphisms in serotonin
system genes have been shown to influence the outcome
of SSRI treatment.
62,64 Many of these results have not
consistently replicated or do not allow the estimation of
prediction accuracy in a clinical population.
65 The rela-
tive lack of reproducibility in pharmacogenetic studies
may reflect the fact that the contributions of individual
polymorphisms may be small and, therefore, large pop-
Clinical research
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66 Given the
complexity of influences “downstream” from genotype,
64
genotype alone may be insufficient to capture the state
of those systems that subserve antidepressant action in
an individual patient. To date, research on possible
genomic factors has not yet yielded reliable predictors. 
Response endophenotypes
The most reliable treatment response predictors iden-
tified thus far are symptomatic and physiologic charac-
teristics of patients that emerge early in the course of
treatment. We propose here the term “response
endophenotypes” to describe this class of predictors.
Specifically, we define response endophenotypes (REs)
as latent measurable symptomatic or neurobiologic
responses of individual patients that emerge early in a
course of treatment and which carry strong predictive
power for individual patient outcomes. In some diseases,
endophenotypic characteristics are elicited by a physio-
logic challenge (ie, glucose tolerance tests, stress elec-
trocardiography).
53,67The distinction of the term response
endophenotype is that it describes a class of markers
that are exclusively observed in response to specific treat-
ment challenges. Although there is evidence that
response to medication is at least in part genetically
mediated, it is not firmly established that the REs pre-
sented below necessarily are heritable. It is therefore
appropriate to consider REs as putative endopheno-
types, pending research to establish heritability and ful-
fillment of the other characteristics of an endopheno-
type.
48
In the prediction of treatment response in MDD, there
are significant advantages to composing endopheno-
types exclusively from measureable changes in an indi-
vidual in response to a specific treatment. First, the fact
that these characteristics are measured “within subjects”
likely enhances stability, statistical reliability, and there-
fore predictive accuracy of the measures. Preliminary
data presented below suggest that use of REs may facil-
itate prompt and accurate matching of patients with the
medication most likely to benefit them. Second, the fact
that RE components are measured in response to newly
administered treatments may overcome some of the
confounding factors inherent in the development of con-
ventional endophenotypes in MDD. It is problematic to
derive prognostic significance from static, cross-sectional
measures in MDD patients; such measurements are
inevitably affected by the number and severity of prior
episodes, the current phase of illness, and the extent and
types of prior and current treatment.
58 Examination of
dynamic measures specific to the current treatment may
detect features that are common across individuals who
will respond to the treatment, irrespective of confound-
ing factors. There are three broad classes of measures
that may change within the first 48 hours to 2 weeks of
treatment that have been identified thus far as potential
predictors of treatment response or remission, and
therefore may be useful as components of an RE. Each
of these is discussed separately below.
Early changes in depressive symptoms
The average time to response in treatment with a pro-
totypical SSRI is 1 month, and to remission is 6 weeks.
5
While some patients continue to enter remission up to
12 weeks or even longer after the initiation of treatment,
the time to symptomatic improvement is much shorter.
Many patients, particularly those with milder symptoms,
show improvement (defined by at least a 20% decrease
in depressive symptoms) within the first 2 weeks of
treatment.
68-71 Although some have suggested that early
response is likely to represent a placebo response,
72,73
early response is in fact twice as likely with medication
as with placebo.
71
The largest meta-analytic study of this topic was per-
formed by Szegedi and colleagues,
74 who examined 6562
subjects treated primarily with mirtazepine, but also with
SSRIs, tricyclic antidepressants (TCAs), and venlafax-
ine. These investigators found that more than 50% of
patients had at least a 20% improvement in depression
rating scores by the end of 2 weeks of treatment. Of
those who did not show early improvement, only 11%
and 4.1% showed eventual response and remission,
respectively. Early improvement was a highly sensitive
predictor of stable response (81% to 98%) or stable
remission (87% to 100%), and so was a positive prog-
nostic sign. However, the usefulness of early symptom
improvement was limited by the poor specificity for sta-
ble response (43% to 60%) or remission (19% to 28%). 
The results of all of these studies are difficult to evalu-
ate because they come from placebo-controlled treat-
ment trials of selected study populations. It is clear that
early symptom improvement is a positive prognostic
sign, and the absence of early improvement is a negative
prognostic sign. The poor specificity of the finding, how-
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based solely upon early symptom improvement; absence
of early improvement by itself is insufficiently powerful
evidence to prompt a change in treatment. It is possible
that early symptom changes could form part of the basis
for REs to reliably predict response and remission to the
specific medication that the patient receives within the
first 2 weeks of treatment. 
Early changes in brain electrical activity
One biomarker that has shown promise as a predictor of
treatment response is quantitative electroencephalog-
raphy (QEEG). Prefrontal QEEG power
75-77 may iden-
tify patients who are most likely to respond to all major
antidepressant medication classes. Research has shown
that QEEG changes in the prefrontal region may reli-
ably identify antidepressant medication responders
within the first 48 hours to 1 week of treatment.
42,78These
findings are consistent with the fact that rhythmic mid-
line prefrontal EEG activity has been shown to reflect
the activity of anterior cingulate and midline prefrontal
cortex,
79 brain areas implicated in mood regulation and
the pathogenesis of depression. 
Based upon these previous results, a multisite study was
designed to test the usefulness of QEEG as a predictor.
The BRITE-MD study (“Biomarkers for Rapid
Identification of Treatment Effectiveness in Major
Depression,” NCT00289523), examined for the first time
the usefulness of a new putative neurophysiologic bio-
marker for medication response and remission, the
Antidepressant Treatment Response (ATR) index.
80
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Figure 1. Study flow chart. Ham-D, Hamilton Depression Rating Scale; SSRI, selective serotonin reuptake inhibitor; EEG, electroencephalography
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sions, at pretreatment baseline (immediately before med-
ication is started) and at the end of 1 week of treatment
with medication. ATR is based upon alpha and theta
band features of frontal brain electrical activity inte-
grated and scaled from 0 (low probability of response or
remission to the medication) to 100 (high probability).
BRITE-MD is the largest single study of any type of neu-
rophysiologic biomarker in MDD undertaken to date (N
=375). All subjects were treated with an initial 1 week of
escitalopram 10 mg, during which time ATR was calcu-
lated. Subjects then were randomized either to continue
escitalopram, switch to bupropion, or receive a combi-
nation of the two medications (Figure 1). 
The outcome measure was the Hamilton Depression
Rating Scale (Ham-D17) score at week 7, with response
defined as a 50% decrease from the baseline score and
remission defined as a final score ≤7. Other putative pre-
dictors examined in BRITE included other biomarkers
(serum drug levels, as well as serotonin transporter [5-
HTTLPR] and postsynaptic serotonin receptor [5-HT2a]
genetic polymorphisms), early changes in symptoms
(measured with the Ham-D17 at 1 week), and clinician
prediction of the likelihood of response (using a clinical
global impression measure at 1 week). 
The Receiver Operating Characteristic (ROC) curve for
predictive accuracy of ATR with escitalopram is shown
in Figure 2. An optimal threshold was chosen on this
curve (58.6) to maximize accuracy in predicting
response, with values above this threshold designated as
a “positive” ATR and those below the threshold as “neg-
ative.” 
A positive ATR biomarker predicted response and remis-
sion to treatment in the escitalopram arm with high accu-
racy. ATR values predicted response with 74% overall
accuracy, 58% sensitivity, 91% specificity, 88% positive
predictive accuracy, and 67% negative predictive accuracy.
ATR also predicted remission with 74% overall accuracy,
61% sensitivity, 82% specificity, 68% positive predictive
accuracy, and 77% negative predictive accuracy. Neither
serum drug level not genetic polymorphisms were signif-
icant predictors of response or remission with escitalo-
pram. Responders at week 7 had significantly larger
decreases than nonresponders in Ham-D17 scores at day
7 (P=0.005), although remitters did not. Clinician predic-
tion based upon global impression of improvement at day
7 did not predict final outcome. Logistic regression
showed that ATR and early Ham-D17 changes were addi-
tive predictors of response, but ATR was the sole signifi-
cant predictor of remission.
80
Another goal of BRITE was to examine the prognostic
significance of a negative biomarker. The overall
response rate to escitalopram in the study was 52%, but
in those with a positive ATR biomarker, the response
rate was 61%. Conversely, in those with a negative ATR
biomarker, the response rate to escitalopram was only
28%. Analyses showed that a low ATR value predicted
not only nonresponse to escitalopram, but also subse-
quent response to treatment among those subjects who
were randomly assigned to receive the antidepressant
bupropion. Subjects with ATR values above the thresh-
old were more than 2.4 times as likely to respond to esc-
italopram as those with low ATR values (68% vs 28%,
P=.001). Subjects with ATR values below the threshold
who were switched to bupropion treatment were 1.9
times as likely to respond to bupropion alone than those
who remained on escitalopram treatment (53% vs 28%,
P=.034, Figures 3 and 4).
81
These differences were statistically significant. One mea-
sure of the potential impact of the use of the ATR bio-
marker is the “number needed to treat” (NNT), namely
the number of patients to whom such a test would need
to be applied in order to realize one improved patient
outcome.
82,83 These results equate to a NNT of 10 to 11,
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Figure 2. Receiver Operating Characteristic curve for ATR prediction of
response to escitalopram treatment. ATR, Antidepressant
Treatment Response index
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ically significant.
84These results must be interpreted with
the caveat that treatment was not assigned prospectively
on the basis of ATR values. 
These results are encouraging, and suggest that ATR
may be useful as a component of a RE for predicting
early in the course of treatment which medication will
be most helpful to an individual patient with MDD. The
fact that ATR data appear to be complementary to early
changes in depression rating scores suggests that a RE
model that integrates symptom and neurophysiologic
measures may be the most useful. 
Gene expression markers
Some of the more intriguing putative biomarkers for
antidepressant treatment response are early changes in
gene expression. Animal and cell culture research, as well
as study of postmortem human brains, indicates that reg-
ulation of gene expression represents a major component
of the mechanism of action of available antidepressants.
The expression of a host of gene families are altered by
antidepressant treatment, including those for trophic fac-
tors that promote cell proliferation, growth, and
resiliency (BDNF, FGF, and VEGF), cell signaling path-
ways, and pathways for neurotransmitter transport and
metabolism, among others.
85,86
Because direct examination of gene expression in
patients’ brains is impractical, recent research has exam-
ined gene expression in peripheral leukocytes, which
share identical genetic material and may exhibit similarly
altered expression in response to antidepressant med-
ications. There have been limited small previous studies
of gene expression through leukocyte mRNA in response
to antidepressant or lithium treatment in patients with
MDD or bipolar disorder.
87-93 These studies have con-
firmed and extended research from animals, showing sig-
nificant differences prior to treatment between bipolar
Clinical research
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Figure 4. Logistic regression models of escitalopram and bupropion
remitters stratified by ATR values. ATR values of subjects ran-
domly assigned to each treatment and who remitted with esc-
italopram or bupropion treatment. Subjects who remitted with
escitalopram (blue) tended to have higher ATR values, and
those who remitted with bupropion (red) tended to have lower
ATR values. Markers represent observed values and lines rep-
resent modeled values. ATR, Antidepressant Treatment
Response index
Adapted from ref 81: Leuchter AF, Cook IA, Gilmer WS, et al.
Effectiveness of a quantitative electroencephalographic biomarker for
predicting differential response or remission with escitalopram and
bupropion in Major Depressive Disorder. Psychiatry Res. 2009;169:124-
131. Copyright © Elsevier, 2009
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Figure 3. Logistic regression models of escitalopram and bupropion
responders stratified by ATR values. ATR values of subjects ran-
domly assigned to each treatment and who responded to esc-
italopram or bupropion treatment. Subjects who responded
to escitalopram (blue) tended to have higher ATR values, and
those who responded to bupropion (red) tended to have lower
ATR values. Markers represent observed values and lines rep-
resent modeled values. ATR, Antidepressant Treatment
Response index
Adapted from ref 81: Leuchter AF, Cook IA, Gilmer WS, et al.
Effectiveness of a quantitative electroencephalographic biomarker for
predicting differential response or remission with escitalopram and
bupropion in Major Depressive Disorder. Psychiatry Res. 2009;169:124-
131. Copyright © Elsevier, 2009
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trophic and transcriptional factors, as well as cell signal-
ing proteins. In some small studies, antidepressant treat-
ment tended to normalize gene expression patterns and
the degree of normalization was proportional to the
degree of symptom improvement.
90,92 No study has uti-
lized microarray-based screening of large numbers of
expressed genes to predict treatment response in MDD,
but one study has performed such screening in a small
number of subjects with juvenile epilepsy and identified
patterns of change in expression that accurately differ-
entiated subjects who were seizure-free on valproate
from those who were not.
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Because of limited research in this area, the gene expres-
sion approach is highly speculative. Furthermore, the bio-
logical basis through which gene expression changes
measured in peripheral blood reflect the central effec-
tiveness of medications admittedly is not fully clear.
There are several possible mechanisms including: i) par-
allel expression changes in the brain and peripheral
blood; ii) leukocyte responses to change in the brain; iii)
responses of the leukocytes to a change in the physio-
logical state of the subject; and/or iv) changes in the com-
position of the leukocyte population. Regardless of the
mechanism, sufficient data exist to support the plausibil-
ity of testing the use of gene expression in peripheral
leukocytes to predict clinical responsiveness to antide-
pressants. Expression profiles could potentially be
applied in the clinic to aid in the treatment of MDD, and
because the fundamental measure is the change in gene
expression within a patient between two time points, each
patient acts as his or her own control, greatly reducing
the artifacts that could arise from directly comparing
gene expression across unmatched subjects, such as sub-
ject-to-subject expression differences due to extraneous
factors such as ethnicity, gender, age, or environment fac-
tors. 
Conclusion
The use of REs for predicting antidepressant treatment
response and remission has the potential to overturn a
flawed biomedical paradigm that forms the basis for clin-
ical research and treatment in MDD, namely, the long
empiric medication trial. Fewer than half of patients
respond to treatment under this paradigm, and fewer
than one third recover. This paradigm leads to prolonged
suffering and increased health care costs. If we were suc-
cessful in identifying response endophenotypes for
patients with MDD, medications would be prescribed
under an entirely new paradigm that relied upon an early
response profile of each patient. The concept of the
response endophenotype shifts from the examination of
endophenotypes and genotypes, which have not proved
highly productive, to the study of dynamic treatment-
emergent characteristics. In this paper we have suggested
early changes in symptoms, brain neurophysiology, and
patterns of changes in gene expression as potential REs.
The RE concept need not be limited, however, to these
few measures. Any early treatment-emergent measures
that could be examined within the individual patient
could be incorporated in this paradigm. We posit that this
paradigm could optimize response and remission rates
with medication and prove superior to the current
approach, leading to earlier symptom improvement,
recovery from the illness, and ultimately profound health
and economic benefits in terms.  ❏
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Un nuevo paradigma para predecir la 
respuesta al tratamiento antidepresivo
El tratamiento actual del trastorno depresivo
mayor emplea una estrategia terapéutica secuen-
cial de ensayo-error que se traduce en demoras
para alcanzar la respuesta y remisión para la mayo-
ría de los pacientes. El tratamiento ineficaz pro-
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una resistencia a posteriores tratamientos. Por
estas razones, es fundamental identificar predic-
tores confiables de la respuesta al tratamiento anti-
depresivo que puedan utilizarse para abreviar o eli-
minar los ensayos prolongados e ineficaces. La
investigación tanto de posibles endofenotipos
como de predictores genómicos aun no ha entre-
gado predictores confiables. Los predictores más
confiables que se han identificado hasta ahora son
ciertas características sintomáticas y fisiológicas de
los pacientes, las que aparecen precozmente
durante el curso del tratamiento. Aquí se propone
el término «respuesta endofenotípica (RE)» para
describir esta clase de predictores, definidos como
respuestas precoces y latentes tanto sintomáticas
como neurobiológicas que se pueden medir en
cada paciente y que tienen un alto poder predictor
para la evolución clínica individual. El empleo de la
RE constituye un nuevo paradigma para los ensa-
yos de tratamientos medicamentosos que tengan
una alta probabilidad de ser inefectivos, ya que
éstos podrían ser suspendidos dentro de una o dos
semanas para dar inicio a otra medicación con
mayor probabilidad de ser eficaz. Los datos aquí
presentados sugieren que los cambios precoces en
los síntomas, en la electroencefalografía cuantita-
tiva y en la expresión génica podrían ser utilizados
para construir REs efectivas. Se postula que este
nuevo paradigma podría llevar a recuperaciones
más precoces de la enfermedad depresiva y a la
larga producir marcados beneficios de salud y eco-
nómicos.    
Un nouveau paradigme de prédiction de la
réponse au traitement antidépresseur
Une stratégie thérapeutique séquentielle par
essais/erreurs est actuellement utilisée dans le trai-
tement du trouble dépressif majeur entraînant  une
réponse et une rémission retardées pour la majorité
des patients. Un traitement inefficace prolongé
allonge la souffrance du patient et augmente les
coûts des soins de santé. De plus, des séquences thé-
rapeutiques longues et infructueuses par antidé-
presseurs contribuent à diminuer les attentes des
patients, à renforcer les opinions négatives et
conditionnent les patients à ne pas répondre au
cours des traitements ultérieurs, contribuant ainsi à
une résistance. Il est donc crucial pour ces raisons
d’identifier des prédicteurs fiables de la réponse au
traitement antidépresseur, pour raccourcir ou éli-
miner les séquences thérapeutiques très longues et
inefficaces. La recherche sur des facteurs prédictifs
endophénotypiques ou génomiques possibles n’est
pas encore fiable. Les facteurs prédictifs les plus
fiables identifiés jusqu’à maintenant sont des carac-
téristiques symptomatiques et physiologiques des
patients apparaissant précocement au cours du trai-
tement. Nous proposons ici le terme « d’endophé-
notypes de la réponse » (ER) pour décrire cette
classe de prédicteurs, définis comme des réponses
précoces latentes symptomatiques ou neurobiolo-
giques mesurables pour chaque patient, avec un
pouvoir prédictif de l'évolution clinique de chacun.
L’utilisation des ER constitue un nouveau para-
digme dans lequel les séquences thérapeutiques de
traitements risquant d’être inefficaces pourraient
être arrêtées dans les 1 à 2 semaines, laissant place
à d’autres antidépresseurs probablement plus effi-
caces. Les données présentées suggèrent que les
modifications précoces des symptômes, l’électroen-
céphalographie quantitative et l’expression des
gènes pourraient être utilisés pour bâtir des ER effi-
caces. Nous postulons que ce nouveau paradigme
pourrait conduire à une guérison précoce de la
maladie dépressive et finalement apporter des
bénéfices économiques et de santé profonds.
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